METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control OngoingThis study tests a new radioactive drug, 225Ac-PSMA-R2, in men with advanced prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to seek out and destroy cancer cells that have a specific marker called PSMA. The trial will check…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Promising new combo therapy for advanced prostate cancer enters final testing phase
Disease control OngoingThis study tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy can help men whose prostate cancer has spread but still responds to hormones. About 1,140 men are taking part. The goal is to see if the combination slows cancer growth and exte…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New pill combo could extend life for men with advanced prostate cancer
Disease control OngoingThis phase 3 trial tests whether adding apalutamide (a daily pill) to standard hormone therapy helps men with metastatic hormone-sensitive prostate cancer live longer and delay disease progression. Over 1,000 participants received either apalutamide plus hormone therapy or a plac…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug cocktail aims to stall prostate cancer in men with PTEN mutation
Disease control OngoingThis study tests whether adding capivasertib to standard hormone therapy (abiraterone plus prednisone and ADT) can slow cancer growth better than standard therapy alone. It includes about 1,000 men with newly diagnosed, hormone-sensitive prostate cancer that has spread and has a …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy may slow prostate cancer spread
Disease control OngoingThis study tests whether adding darolutamide to standard hormone therapy (ADT) can delay cancer worsening in men with metastatic hormone-sensitive prostate cancer. About 223 men will receive darolutamide plus ADT, and their results will be compared to men from an earlier study wh…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug combo shows promise for chinese men with advanced prostate cancer
Disease control OngoingThis phase 3 study tested whether adding enzalutamide (Xtandi) to standard hormone therapy (ADT) helps Chinese men with metastatic hormone-sensitive prostate cancer. 180 participants received either enzalutamide plus ADT or a placebo plus ADT. The main goal was to see how long it…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Astellas Pharma China, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New study tracks Darolutamide's Real-World impact on advanced prostate cancer
Disease control OngoingThis observational study follows about 1,600 men with metastatic hormone-sensitive prostate cancer who are taking darolutamide plus hormone therapy, with or without chemotherapy. Researchers will track how many men have undetectable PSA levels after one year, as well as overall s…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Triple threat: new combo aims to tame metastatic prostate cancer
Disease control OngoingThis phase 2 trial tests whether adding enzalutamide to standard hormone therapy and chemotherapy can better control metastatic prostate cancer that still responds to hormones. About 40 men with advanced disease will receive all three drugs. The main goal is to see how many achie…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Prostate cancer study tests Two-Drug vs. Three-Drug combo
Disease control TerminatedThis study aimed to compare two treatment plans for men with low-volume metastatic prostate cancer that still responds to hormone therapy. One group would receive hormone therapy plus abiraterone, while the other would get those two drugs plus chemotherapy (docetaxel). The goal w…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Real-World study compares two prostate cancer drug combos
Knowledge-focused OngoingThis study follows about 500 men with advanced prostate cancer that still responds to hormone therapy. Researchers are comparing two drug combinations (apalutamide or enzalutamide plus standard hormone therapy) to see how well they work in real-world settings. The goal is to unde…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Janssen-Cilag Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
New study tracks Real-World prostate cancer treatments across canada
Knowledge-focused OngoingThis study collects information from medical records of 700 Canadian men with metastatic hormone-sensitive prostate cancer (mHSPC). Researchers want to see how doctors actually combine treatments like hormone therapy, newer drugs, or chemotherapy in everyday practice. No new trea…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC